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ABSTRACT
The incidence of oropharyngeal cancer (OPC) related to infection with human papillomavirus (HPV) is
rising, making it now the most common HPV-related malignancy in the United States. These tumors
present differently than traditional mucosal head and neck cancers, and those affected often lack classic
risk factors such as tobacco and alcohol use. Currently, there are no approved approaches for prevention
and early detection of disease, thus leading many patients to present with advanced cancers requiring
intense surgical or nonsurgical therapies resulting in significant side effects and cost to the health-care
system. In this review, we outline the evolving epidemiology of HPV-related OPC. We also summarize the
available evidence corresponding to HPV-related OPC prevention, including efficacy and safety of the
HPV vaccine in preventing oral HPV infections. Finally, we describe emerging techniques for identifying
and screening those who may be at high risk for developing these tumors.
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Head and neck cancer accounts for 3% of malignancies in the
United States, with more than 63,000 Americans diagnosed
with this disease and 13,000 dying from it annually.1
Oropharyngeal cancer (OPC) represents a significant portion
of head and neck cancers.2 OPCs include those found in the
soft palate, base of tongue, lingual and palatine tonsils, and
surrounding tissues. While tobacco and alcohol exposure have
long been established as risk factors for OPC, in recent dec-
ades there has been an increase in a subset of OPC linked to
human papillomavirus (HPV).3 HPV is a double-stranded
DNA virus with predilection for squamous epithelium.4
Cryptic epithelium overlying the tonsils and tongue base
acts as a reservoir for the virus, providing access to its basal
layer for viral replication.2 Over time, malignant transforma-
tion can occur when viral oncoproteins disrupt tumor sup-
pression genes in native tissue. Reticulated crypt epithelium in
the oropharynx is unique to this anatomical location in the
head and neck, and may explain why HPV is estimated to be
five times higher in the oropharynx when compared to the
oral cavity, larynx, or hypopharynx.5 Although there are many
types of HPV, the overwhelming majority of HPV-related
OPC cases are caused by HPV16.
While data suggest an overall stable incidence of HPV-
negative OPC, the incidence of HPV-related OPC is rising,6
and it will continue to be a major factor in national health
care related to cancer treatment. The rise in incidence of
HPV-related OPC makes it now the most common HPV-
related malignancy in the United States.7,8 According to the
Centers for Disease Control and Prevention (CDC), there
were 11,788 reported cases of cervical carcinoma and 18,917
cases of OPC, including 15,479 (82%) among men and 3438
(18%) among women in 2015.7 In the United States, HPV
DNA can now be identified in more than 70% of all new cases
of OPC.9 Similar trends are seen in Northern Europe.10
Patients affected are typically in their fifth or sixth decade of
life, have an earlier sexual debut, and a higher number of
lifetime oral and vaginal sex partners than those affected by
HPV-negative OPC.8,11,12 In addition, these individuals are
more often male, of higher socioeconomic status, and less
likely to have a history of tobacco or alcohol abuse.13
Oral HPV infection is the primary risk factor for HPV-related
OPC, and over 90% of oral HPV infections are sexually
acquired.14 Therefore, it is no surprise that the number of oral
sexual partners is the behavioral factor most strongly and specifi-
cally associated with OPC. Differences in sexual behavior between
countries may contribute to the differences in global trends of
HPV-related OPC.10
In addition to viral exposure, concomitant tobacco use
may also play a part in the development of HPV-related
OPC. Gillison and colleagues performed a multivariable
analysis inclusive of individuals aged 14–69 y, looking at
factors independently associated with prevalent oral HPV
including age, sex, lifetime number of sexual partners, and
current smoking intensity.15 Although adjustment for other
factors dampened the first age-related peak in oral HPV
prevalence, the bimodal age pattern remained statistically
significant. Prevalence increased with number of lifetime
sexual partners and number of cigarettes smoked per day.
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As a result, disease prevention efforts should also include
attention to tobacco cessation.
Clinical behavior, treatment morbidity, and cost
The clinical behavior and presentation of HPV-related OPC are
different from its HPV-negative counterpart. In patients with
HPV-related OPC, the most common presenting symptom is
a neck mass, while those with HPV-negative OPC are more
likely to complain of a sore throat and dysphagia.16 On presenta-
tion, they are more likely to have early T-stage (T1/T2) and
advanced cervical nodal disease (N2/N3), when compared to
HPV-negative tumors.10,17 However, while involvement of cer-
vical lymph nodes reflects more advanced disease, such patients
with HPV-related OPC have better survival outcomes and
response to treatment than those with HPV-negative OPC.18,19
The standard treatment for OPC has been concurrent radia-
tion and chemotherapy, with an increasing role for upfront
surgical approach with advances in transoral surgery.20
Although survival rates are high, long-term toxicity and poor
functional outcomes are still a concern for patients who have
survived their cancer (Table 1).14,21 Since the oropharynx is
crucial to important everyday functions such as speech, swallow,
and airway patency, both surgical and medical treatment of
tumors in this area can result in significant morbidity. Patients
can have long-lasting dysphagia and problems with speech such
as velopharyngeal insufficiency from post-surgical changes,
post-radiation effects, and chemotherapy. Additional side effects
include nausea and vomiting, dry mouth, progression of dental
disease, loss of taste, difficulty with mouth opening, and even
osteoradionecrosis of the mandible (Figure 1).22-26 While most
of these issues improve over time with treatment and physical
and/or speech therapy, some patients have long-standing dys-
function and require gastrostomy tubes for nutritional health, or
tracheostomies for airway maintenance or pulmonary hygiene.21
In fact, a retrospective review by Vatca et al. suggests that high-
grade mucositis with concomitant weight loss from radiation
therapy is worse in HPV-related OPC compared with HPV-
negative OPC.27 Thus, efforts are underway to investigate the
feasibility of de-intensified chemoradiation therapy and to
expand the indications for surgical therapy in hopes of decreas-
ing acute and long-term morbidity and improving functional
outcomes.28,29
Although HPV appears to be a distinct risk factor from
smoking in the development of OPC, tobacco exposure can
also play a role.15 Although patients with HPV-positive OPC
are less likely to be smokers, those who do have a significant
current or past smoking history have been found to have sig-
nificantly worse disease control with treatment.13,30,31 Maxwell
and colleagues found that current tobacco users with advanced,
HPV-positive OPC are at higher risk of disease recurrence
compared with never-tobacco users after chemoradiation ther-
apy. In their study cohort, 35% of HPV-positive ever-tobacco
users recurred compared with only 6% of HPV-positive never-
users and 50% of HPV-negative patients.30
In addition to the morbidity from treatment and risk for
cancer-related mortality, there are significant costs associated
with the management of OPC, with one study showing an
estimated cost of $140,000 per new patient in the first 2 y of
treatment and surveillance, not accounting for additional
costs due to loss of productivity.32 Based on numbers from
2004 to 2007, it was estimated that the mean lifetime cost per
new case of HPV-related head and neck cancer was $43,200
with a total annual cost in the United States of $306 million.33
Another study by Moore et al. compared cost between differ-
ent treatment modalities and found that the mean cost of
therapy (private payers/government payers) ranged from
$37,435/$15,664 in those treated with surgery alone to
$198,285/$57,429 when chemoradiation was employed.34
Rationale for prevention and screening
In response to the emerging epidemic of HPV-related OPC, and
the morbidity and costs associated with treating these cancers,
much attention has turned to the prevention and early detection
of disease. A United States national initiative called Healthy
People 2020 aims to decrease the number of deaths due to
OPC by 10%, mainly through improving immunization rates
to reduce preventable infections.35 Current vaccination rates are
low, especially in males who are most often affected by these
cancers.36 Recent statistics estimate that about 65% of girls and
56% of boys between ages 13 and 17 y have received the first dose
of the HPV vaccine.37 Moreover, due to the lack of level one
evidence showing a reduction of premalignant lesions and OPC
with vaccination, prevention of OPC is not an approved vaccine
indication by the Food and Drug Administration (FDA). This
creates a barrier to increasing public education and awareness on
a large scale.
In addition to the challenges posed in implementing success-
ful prevention campaigns, there is an increasing need to develop
effective screening techniques to allow for early detection of
disease, especially for those who have not received the vaccine.
Challenges to screening include lack of a precursor lesion and
a long latency period between exposure to virus and onset of
disease. Multiple studies suggest that the timing between
Table 1. Adverse effects of nonsurgical therapy.
Adverse effect(s) Patients affected
Taste disturbance23 88%
Nausea and vomiting24 36%
Dry mouth25 29–38%
Esophageal stricture26 5%
Figure 1. Patient with osteoradionecrosis of the mandible from radiation therapy.
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exposure to HPV virus and development of cancer exceeds
a decade, and can be as long as 30 y.10,38 In this review, we
provide an update on the current status of HPV-related OPC
prevention in the United States as well as evolving approaches to
screening. In addition, we outline some of the challenges posed
to these efforts as well as potential areas for future study.
Prevention of HPV-related OPC
Lifestyle modifications
The behavioral risk factor most associated with HPV-related
OPC is oro-genital sex. As a result, primary prevention
through safe sexual practices such as condoms and barrier
contraceptives is a critical prevention strategy. Gupta et al.
performed a cross-sectional analysis of National Health and
Nutrition Assessment Survey from 2009 to 2014 to see if there
is a correlation between barrier contraceptive and prevalence
of oral HPV 16/18 infection. They found that after adjusting
for all variables associated with HPV positivity, individuals
reporting barrier use were significantly less likely to be HPV
16/18 positive when compared to those not using barrier
during oro-genital sex. It is important to note that this popu-
lation had not received the HPV vaccine.39 Therefore, barrier
contraceptive is an important prevention strategy for those
who are beyond the eligible age for vaccination. While the
CDC recommends use of barrier contraceptives such as con-
doms and dental dams during oro-genital sex to reduce
transmission of sexually transmitted infections, there needs
to be stronger emphasis on the correlation between this and
decreasing risk of developing OPCs.
As mentioned above, Gillison et al. demonstrated that
tobacco smoking also significantly correlates with oral HPV
infection,15 and such use can negatively impact survival if
OPC develops.30 As a result, efforts of smoking cessation are
critical in an effort to reduce oral HPV infection as well as the
development of OPC and other cancers.
Vaccination
In 2006, the pharmaceutical company, Merck and Co., intro-
duced a quadrivalent HPV vaccine called Gardasil 4. The
vaccine protected against HPV 6, 11, 16, 18 with the initial
goal of preventing HPV-related cervical cancer in women.40
Since the introduction of Gardasil 4, a bivalent (Cervarix) and
a nine-valent vaccine (Gardasil 9) were also created and
approved for use. Gardasil 9 is the most recently approved
vaccine, and its safety was ascertained in clinical trials with
over 15,000 participants prior to its FDA approval.41 In addi-
tion to the original four HPV strains covered by the quad-
rivalent version, Gardasil 9 also protects against HPV types
31, 33, 45, 52, 58 and thus covers strains that cause over 90%
of HPV-related cancers including HPV-related OPC.
By 2011, the CDC recommended routine HPV vaccination
for both girls and boys between 9 and 26 y old for the
prevention of cervical and anogenital HPV cancers. Ideally,
the vaccine would be administered at 11 or 12 y of age with
the goal of preceding sexual debut and capturing the robust
immune response that is mounted at that age.40,42 In theory,
later vaccination would be less effective as many individuals
would have already contracted a persistent infection by
a high-risk HPV virus prior to that time, and may therefore
not be protected. However, recent studies have shown that the
immune response to HPV vaccination in men aged 27–45 y
was comparable to those observed in younger men but with
unknown efficacy rates of preventing persistent HPV infec-
tions in these older patients.43 On October 5, 2018, the FDA
approved a supplemental application for the Gardasil 9
Vaccine, expanding its approved use to include women and
men aged 27–45 y.
Though the CDC recognizes that persistent infection with
oncogenic HPV types can cause cancers at non-cervical sites,
the FDA has not officially approved the vaccine for preven-
tion of OPCs. This contributes to a lack of awareness regard-
ing the correlation between HPV vaccination and prevention
of OPC, even among medical professionals. This was high-
lighted by a study in Louisiana by Mehta and colleagues
surveying members of the Louisiana Chapter of the
American Academy of Pediatrics.44 The study demonstrated
that 15.5% of the pediatricians polled were not aware of the
link between OPC and HPV, and less than half knew that
HPV-related OPC incidence was increasing. Despite CDC
recommendations, the study found that only 89.7% of pedia-
tricians routinely recommended the HPV vaccine, while 5.2%
occasionally offered or only at caregiver request and the
remaining 5.2% did not offer the vaccine at all. This, com-
bined with the fact that less than 1% of the US population in
2014 recognized HPV as a risk factor for development of head
and neck cancer,45 may in part be responsible for lower
vaccine uptake compared to the others in the adolescent
series.
Lack of FDA approval for use of the vaccine to prevent
HPV-mediated OPC stems from the inability of clinical trials
to directly demonstrate vaccine efficacy against oropharyngeal
HPV-related disease. Until relatively recently, regulatory
agencies required a clinical disease end point for trials regard-
ing HPV vaccine efficacy. Precancerous lesions, which would
serve as a disease end point, are not established in OPCs.
Furthermore, since cancer may not develop for many years
after initial infection with the virus, a trial showing
a correlation between increasing vaccine use and decreasing
OPC rates may not be available for many decades.
In 2014, the World Health Organization recommended that
efficacy against incidence and persistent HPV infection can be
a surrogate for disease risk.46 A number of studies have provided
evidence that HPV vaccination decreases the rate of HPV-
related infections and are likely to reduce the incidence of
cancers of the oropharynx. A double-blind randomized con-
trolled trial conducted in Costa Rica by Herrero et al. evaluated
the efficacy of the bivalent vaccine in reducing oral HPV infec-
tion 4 y after vaccination. They observed a 93.3% reduction of
prevalent oral HPV 16 and 18 infections in the vaccine arm
compared to the control arm.47 Another recent study by Hirth
et al. concluded that vaccine-type oral HPV prevalence was
lower in individuals who received the HPV vaccine compared
to unvaccinated individuals.48 Similar results were shown by
Chaturvedi et al.36 Their study demonstrated that HPV vaccina-
tion was associated with an estimated 88% reduction in
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prevalence of vaccine type oral HPV 6, 11, 16, 18 infections
among vaccinated young adults in the US. As noted in the
prior studies, findings consistently show a significant decrease
in these HPV infections in the vaccinated population compared
to the unvaccinated men and women in the United States.
However, because of a vaccination rate of only 18.3% between
2011 and 2014 among individuals 18–33 y of age, the popula-
tion-level effect of HPV vaccination on oral HPV 6,11,16,18 was
a modest 17%.36 Other recent studies have addressed concerns
that vaccination against some but not all HPV types may intro-
duce a competitive advantage for non-vaccine types. This would
lead to an eventual decrease effectiveness of the vaccine. A study
by Tota et al. obtained data from the Costa Rica Vaccine trial and
PATRICIA trial to compare incidence of non-protected HPV
infections across the trial arms after 4 y. Their results revealed
similar or higher incidence of non-protected HPV types in the
control arm compared with the HPV arm across all their ana-
lyses, which supports that type replacement is unlikely to occur
among vaccinated individuals.49 This further supports vaccina-
tion as a primary prevention strategy.
Currently available HPV vaccines are 90–100% effective
in preventing genital HPV infections, and the global cervical
cancer burden is projected to be dramatically reduced by
2050 due to both the vaccine and the improved cervical
screening.10 However, unlike the Papanicolaou test for cer-
vical cancer, there is no current reliable screening method
to detect precancerous OPCs. As a result, expanding the use
of the HPV vaccine is that much more critical when redu-
cing the number of patients affected by HPV-related OPC.
It has been estimated that, by vaccinating boys and men,
5416 and 51,168 additional cases of HPV-related OPC
would be prevented at 50 and 100 y, respectively.50
Additionally, the societal cost of HPV vaccination has
been predicted to be well below the $50,000/Quality-
Adjusted Life Year threshold used to determine cost-
effectiveness of public health initiatives.51 Such evidence
strongly supports continued efforts to improve vaccination
rates in both girls and boys.
Screening for HPV-related OPC
As previously mentioned, the most common presenting
symptom of HPV-related OPC is a lateral neck mass. Thus,
many patients have developed regional metastasis at presenta-
tion, and by definition have more advanced disease. In fact,
one study showed that of 1907 patients with HPV-related
OPC, 73% were diagnosed with advanced locoregional
disease.17 As a result, there is a tremendous need to develop
an approach to identify occult lesions at an earlier stage to
allow for successful and less morbid treatment. For
a screening technique to be beneficial, it is first necessary to
determine a high-risk population. An ideal test would be
cheap, minimally invasive, and appropriately sensitive to
identify a high proportion of subclinical lesions (i.e. a high
negative predictive value).
While there are currently no effective screening methods
and no precancerous lesion correlates for HPV-related OPC,
there are emerging techniques. These advances show promise
through serologic testing14 and imaging52,53 that may aid in
identifying high-risk individuals as well as subclinical lesions,
respectively. Here, we outline some of these approaches that
may allow for a more focused assessment of those predisposed
to developing HPV-related OPC.
Population screening
Population screening for OPC is difficult since at present
there are no precursor lesions. Moreover, the mucosal surface
of the oropharynx is much more challenging to examine than
the cervix as many lesions start in the reticulated epithelium
at the depth of tonsillar tissue crypts, thus concealing them
from visual inspection. As a result, efforts have focused on
first narrowing the population down into those at highest risk
for development of disease. Men aged 50–65 y with multiple
sexual partners would be an appealing target demographic for
screening programs given the higher incidence of these
tumors in this demographic group.33 However, further defini-
tion of the true level of risk of such a group is currently under
investigation.54
Oral HPV screening
An initial approach considered for assessment was to use oral
HPV screening. This technique evaluates for the presence of
HPV DNA in saliva and can be even used to focus specifically
on high-risk HPV such as HPV 16. However, while this
technique can be effective in demonstrating active HPV infec-
tion, it is of little utility in screening for HPV-related OPC as
the majority of individuals either go on to clear the infection
or fail to progress to malignancy. Consequently, the use of
oral HPV screening has been discouraged as a screening tech-
nique to identify OPC.55
HPV serology
One area that has shown particular promise in assessing high-
risk populations is to screen for serum antibodies to HPV 16
proteins. Such an approach may allow for at-risk individuals to
be identified prior to progression of disease. In an early study by
Mork et al., serum positivity to the L1 capsid protein of HPV 16
conferred a 14-times increased risk of developing OPC, when
linking findings from a Nordic serum bank and tumor
registries.56 While these findings were encouraging, these anti-
bodies represent the body’s cumulative exposure to HPV 16 and
are not specific to anatomic site. Moreover, they do not reflect
expression of HPV oncoproteins necessary for carcinogenesis.
In 2013, Kreimer and colleagues identified that serum
antibodies to the E6 oncoprotein of HPV 16 were a better
marker for predicting cancer.38 In this important study, par-
ticipants came from the European Prospective Investigation
Into Cancer and Nutrition cohort and 638 patients who went
on to develop head and neck cancer and 1599 controls with
no evidence of cancer were evaluated. Pre-diagnostic serum
samples were collected and analyzed for antibodies against
multiple HPV 16 proteins as well as other subtypes of HPV.
All told, HPV 16 E6 seropositivity conferred a 274 times
increased risk of developing OPC, being present in 34.8% of
OPC patients compared to 0.6% in other head and neck
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cancer patients and control patients. This positive finding was
found on average 6 y before diagnosis and was observed in
some instances more than 10 y before the cancer was found.
Such seropositivity has been shown to result in a 10-y cumu-
lative risk of developing HPV-related OPC of 6.2% in men
and 1.3% in women, compared to 0.04% in seronegative
controls.57 Additional study has also shown that higher pre-
treatment HPV 16 E6 antibody titers can predict recurrence,
while E6 and E7 titers decreased when reassessed in the early
and late posttreatment setting.58
Transcervical ultrasound
In individuals with HPV-related cancer in a neck mass, as well
as those found to be high risk by either positive serology
screening or other methods, transcervical ultrasound can be
used as an additional means for assessment. The use of ultra-
sound has long been standard in the evaluation of thyroid
lesions and cervical adenopathy, and it can aid in guidance of
fine needle aspirations, especially in cystic nodal disease like
what is often observed in HPV-related cancers.
In addition to assessment of nodal disease, the use of
transcervical ultrasound has now been applied to evaluate
the oropharynx in an effort to identify occult tumors, espe-
cially those developing in crypts of the palatine and lingual
tonsils, not visible on surface examination.59,60 While such an
approach to screening is not widely utilized, at present, it is
particularly appealing in that it is relatively cheap, minimally
invasive, and results in no exposure to ionizing radiation or
intravenous contrast.
Mucosal imaging
The lack of an identifiable early lesion presents a significant
challenge when evaluating for premalignant and malignant
lesions of the oropharynx. The conventional approach following
a head and neck physical examination is to offer fiber-optic
nasopharyngoscopy using standard white light imaging (WLI).
While the optics of contemporary endoscopes allows for
improved definition and magnification, small and superficial
lesions may be missed due to the subtle difference in appearance
of normal and abnormalmucosa. Two techniques that have been
applied to augment this aspect of mucosal screening are narrow
band imaging (NBI) and endoscopic lifetime imaging.
NBI was first described for use in the gastrointestinal tract
by Sano in 2001.61 Using this technology, filters of spectral
regions centered at 415 nm (blue light) and 540 nm (green
light) are used, excluding other signals from visible spectrum,
thus highlighting the vascularity near the tissue surface.
Images are obtained through the nasopharyngoscope that
can allow for identification of subclinical lesions (Figure 2).
Such an approach was used in a multicentered randomized
controlled trial and found NBI detected superficial mucosal
lesions of the head and neck more often than WLI (100% vs.
8%) and had a sensitivity and accuracy of finding lesions of
100% and 86.7%, respectively.62 This technique has also been
shown to be helpful in identifying the primary lesion in
patients with neck cancer with an unknown head and neck
primary site. One study by Ni and colleagues evaluated 53
patients with cervical lymph node metastases with no identifi-
able primary site seen on physical examination, computed
tomography scan (CT), magnetic resonance imaging scan
(MRI), and laryngoscopy. The use of NBI allowed for identi-
fication of lesions in 47% patients.63 Similarly, Hayashi et al.
used NBI to screen 46 of such patients and a primary was
identified in 35% of individuals. The study did not report
specifically on percentage of lesions positive for HPV.64
Lifetime-resolved laser-induced imaging is another approach
that has shown recent promise in mucosal imaging. Using this
technique, laser energy is applied to a surface and the reflected
signal representing the induced autofluorescence of the tissue is
captured. Data have shown that the autofluorescence character-
istics of normal, dysplastic, and cancerous head and neck
mucosa are different, suggesting that this technique may have
a role in cancer screening (Figure 3).65,66 Despite their promise,
all mucosal imaging techniques have limitations in OPC screen-
ing as many tumors originate in the depths of tonsillar crypts
and thus are not well seen on surface evaluation.
Future directions
There are currently no reliable biomarkers that can be used for
tumor screening or to evaluate for cancer recurrence for head
and neck cancer. With increased availability of robust
Figure 2. Patient with T1N2A oropharyngeal cancer status post definitive chemoradiation. (a) Distal chip video laryngoscopy revealed post-treatment radiation
edema with no evidence of mucosal disease delineated by red arrows. (b) NBI revealed a mucosal abnormality delineated by blue arrows. Biopsy was consistent with
high-grade dysplasia. Image is borrowed with permission from Dr Peter Belafsky.
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sequencing technology, however, methods have been developed
looking at saliva and serum tumor DNA as a potential approach.
This concept of measuring serumDNA is particularly exciting as
it would represent a minimally invasive way to assess for sub-
clinical lesions and monitor for disease response and recurrence.
Circulating cell-free DNA (cfDNA) has been proposed as one
such method. This approach centers around the fact that when
tissue dies, its DNA is released into serum and circulates extra-
cellularly prior to being metabolized over the next 15–20 min.
Consequently, any analysis provides a reflection of tissue under-
going rapid turnover as can be seen in active malignancy. Virally
mediated cancers are particularly well suited for such “liquid
biopsies” as they have known viral DNA incorporated into the
host DNA that can be queried. In fact, this approach has demon-
strated tremendous promise in screening for Epstein-Barr virus
(EBV)-related nasopharyngeal cancer.67 In a trial where 20,174
asymptomatic participants were screened, 309 individuals were
found to have persistently elevated levels and 300 ultimately
went on to undergo nasal endoscopy with or without MRI.
Thirty-four of those subjected to further screening were found
to have nasopharyngeal cancer, with the majority being either
stage I or II, while only one patient with a negative initial test is
found to have a nasopharyngeal cancer in the year following
screening, thus yielding a sensitivity and specificity of the tech-
nique of 97.1% and 98.6%, respectively.
HPV-related OPC also appears appropriate for assessment
with cfDNA. Such tumors often have nodal metastases with sig-
nificant necrosis, thus likely shedding large amounts of tumor
DNA. In addition, with the known component of the HPV DNA,
as well as other differentiating patterns such as DNAmethylation
and fragment size, techniques are under development that may
soon allow for early identification of these lesions through blood
analysis. Wang et al. studied the potential for looking at tumor-
specific DNA in saliva and serum in head and neck cancer
patients.68 They found oral cancer was more likely to show eleva-
tion in saliva tumor DNA while tumors in the oropharynx were
more likely to have elevations in their serum levels. Additionally,
the combined use of posttreatment saliva and plasma HPV 16
DNApositivity was found to be 69.5% sensitive and 90.7% specific
in predicting recurrence within 3 y of therapy completion,
suggesting a potential role in surveillance.69 Similar findings
were observed in a recent publication by Hanna and colleagues
where HPV cfDNA levels correlated with total tumor burden, and
higher levels as well as higher total tumor burden resulted in
worse overall survival.70 Moreover, using this method, cfDNA
levels were also found to have a corresponding change at
a median of 16 d prior to restaging scans reflecting either disease
response or progression. With the promise seen from these early
results, such methods are being used to prospectively evaluate
high-risk individuals to determine if early lesions can be identified
prior to symptom development. While these approaches alone
would not be sufficient for surveillance, it could help augment
current surveillance techniques such as history, physical examina-
tion, transcervical ultrasound, and positron emission tomography
imaging.
Limitations
Since this paper is a narrative review, there is a lack of
objective and systematic selection criteria for the papers
included. Papers included in discussing the topic range from
case reports to randomized controlled trials and therefore
vary in level of evidence. While we chose to only use papers
which we felt provided high quality of information, lack of
methodological selection of these papers lead to bias of our
interpretation and conclusions.
Conclusions
HPV-related OPC carries significant morbidity, mortality, and
substantial cost to the health-care system. With its increasing
incidence, importance should be placed on prevention of this
disease and early diagnosis through effective screening techni-
ques. While new screening methods are still underway, empha-
sis should be placed on prevention through greater public
awareness of risk factors associated with HPV, behavioral
changes to mitigate these risks, and widespread use of the
vaccine. Furthermore, while HPV-related OPC has improved
survival compared to HPV-negative OPC, it is important to
remember that tobacco users have significantly worse disease
Figure 3. This intraoperative image shows the use of lifetime tissue autofluorescence for identification of pathologic mucosa. A laser is aimed at the surface and the
signal returning from the tissue is interpreted. The signal for pathologic mucosa has been shown to be distinctly different than normal and is demonstrated by
a different shade on the color scale. Such an approach could be very useful in cancer screening. However, small submucosal lesions may avoid detection.
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control with treatment. Although HPV-vaccination efforts show
promise in protecting against oral HPV infection, clinical trials
supporting vaccine efficacy against oropharyngeal HPV-related
disease are currently lacking. This has contributed to a delay in
the FDA’s approval of the vaccine for prevention of HPV-
related OPC. Therefore, further research in showing vaccine
efficacy is critical. For those already at risk due to prior expo-
sure, development of effective screening techniques will be
crucial to allow for early detection of subclinical lesions. While
some methods appear useful in screening those in high-risk
cohorts, other techniques have application in individual patient
assessment as well as in disease surveillance. Further research is
needed to determine the optimal means to combine these and
other methods to allow for optimal disease prevention and early
detection on a larger scale.
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